Survivorship care: Understanding the sequelae of breast cancer treatment

Issue: BCMJ, Vol. 60, No. 2, March 2018, page(s) 109-115 Articles
Connie G. Chiu, MD, FRCSC, Brenda Lau, MD, FRCPC, FFPMANZCA, CGMIS, MM, Alan Nichol, MD, CCFP, FRCPC

Management of posttreatment risks, including arm lymphedema, cosmesis, and chronic pain, may help patients navigate their recovery after breast cancer treatment.

ABSTRACT: Survivorship care has improved as the sequelae of breast cancer treatment have become better appreciated and understood in an era of increasing focus on patient-centred care. Development of arm lymphedema is a risk following axillary treatment. The introduction of less-invasive surgical procedures has resulted in decreased rates of lymphedema. It is now recognized that physical activity and routine medical procedures on the treated arm are safe and do not increase the risk of lymphedema. Patient education regarding early detection of lymphedema and timely referral to physiotherapy may be beneficial. Cosmesis may represent another survivorship concern. The appearance of the treated breast may impact self-image and recovery. The decision between breast conserving therapy and mastectomy is complex and is best supported through patient education and a patient-centred process of care. Lastly, chronic posttreatment pain may affect certain individuals. The optimal management of posttreatment pain involves a multimodal early-intervention strategy. This approach can be instituted in the pretreatment, intraoperative, and postoperative phase, using balanced multimodal analgesics, self-management techniques, and upper body physical recovery. This article reviews current approaches to arm lymphedema, posttreatment cosmesis, and reducing posttreatment pain.

An increasing number of patients in British Columbia are survivors of breast cancer and are navigating life in their “new normal.” Survivorship care is an evolving field that strives to recognize, understand, and manage the issues that arise in the posttreatment phase. For some women, the sequelae of treatment have a significant and long-lasting impact on their physical, emotional, and psychological health. Some concerns in survivorship care are arm lymphedema, cosmesis, posttreatment pain, and cancer surveillance.

Arm lymphedema
The reported incidence of arm lymphedema following breast cancer treatment is highly variable. The estimated risk for patients undergoing axillary lymph node dissection (ALND) is 20%, compared with 5% for sentinel lymph node biopsy (SLNB).[1] However, a more clinically meaningful and relevant interpretation of risks is the presence of severe edema alone (defined as more than a 5-cm difference in arm circumference), which has an estimated incidence of 3.0% for ALND and 0.5% for SLNB.[2] The use of axillary radiation is an independent and added risk factor for development of clinically significant lymphedema, with an incidence of 8% in patients undergoing combined axillary surgery and radiation.[3] The onset of lymphedema is typically seen within 3 years of axillary intervention,[1,4] while the ongoing risk beyond 3 years is estimated at 1% per year to at least 20 years.[4] Prevention strategies focus on reducing axillary intervention and other risk factors. Once lymphedema is diagnosed, management efforts focus on preventing progression and addressing associated symptoms.

Arm circumference is a commonly utilized and simple clinical measurement for assessing lymphedema. Measurements are taken at 15 cm above and below the medial epicondyle. Diagnosis is based on the difference between the treated and untreated arm, or between the preoperative and postoperative arm.

Differences greater than 2 cm indicate clinical lymphedema, which is further classified as mild (2 to 3 cm), moderate (3 to 5 cm), or severe (more than 5 cm).[5]

Risk factors
The mechanism leading to lymphedema following axillary intervention is not well understood but is thought to involve posttreatment fibrosis obstructing remaining lymphatic channels. Once clinically evident lymphedema develops, the changes are generally irreversible. Although theoretically lymphedema can be reversed in the subclinical phase, there are currently no diagnostic or intervention tools available for common clinical use.

While avoidance of trauma to the treated extremity, including blood pressure measurement and skin puncture, may appear sensible, the evidence for this is extremely poor and a growing body of literature does not support these precautions.[6]

The impact of blood pressure measurement on lymphedema risk was addressed in four recent level 2 and 3 studies, three of which did not identify a significant association.[7-9] Other studies evaluating the use of a pneumatic tourniquet during hand surgery in patients with previous axillary surgery did not demonstrate increased risk of lymphedema.[10,11]

The risk of skin puncture leading to lymphedema has been considered in 11 studies. Those that endorsed avoidance of skin puncture were primarily historical retrospective observational studies or single-subject case reports.[6] Among the three prospective cohort studies available, one identified a significant risk of lymphedema in patients with a history of skin puncture,[12] although recall bias has since been raised as an issue, and subsequent studies have found no significant association between skin puncture and lymphedema.[7-9]

Although using the untreated arm for medical procedures when possible remains a sensible precaution, repeatedly advising patients to limit use of the  treated arm may cause unnecessary anxiety and restrict activities. Given the evidence, it is reasonable for medical teams to move away from overly restrictive advice. Patients can be reassured that studies have demonstrated that blood pressure readings and medical procedures on the treated arm do not increase the risk of lymphedema.

Prevention and management
The only risk factors for lymphedema identified consistently are axillary surgery, axillary radiation, high body mass index, and cellulitis.[1,2,4,8,9,12] Cellulitis represents a proven and widely accepted risk factor for lymphedema. Thus, early recognition and treatment of extremity infections is important. Avoidance of ALND when feasible may also reduce the risk of lymphedema.

Randomized controlled trials (RCTs) have shown upper extremity exercise and weight training to be safe following axillary intervention, with no increased risk of lymphedema in patients without lymphedema at baseline.[13] Physiotherapy and/or manual lymphatic drainage produced encouraging results in modifying the risk of lymphedema,[14,15] while patient education regarding early recognition of lymphedema, timely referral to physiotherapy, and use of compression sleeves were shown to be useful management strategies.[14-16]

Once a cancer is surgically excised, patients must live with the new appearance of the treated breast. Using patient-reported outcomes, researchers have demonstrated the importance of cosmesis and its impact on self-image and recovery.[17] Of the numerous validated psychometric patient-reported outcome measures (PROMs) available, the BREAST-Q17 has become one of the most widely utilized for breast reconstruction and breast conserving surgery (BCS).[18]

Breast conserving surgery versus mastectomy
The nononcologic goals of breast conserving surgery include preservation of the breast’s esthetic appearance, sense of wholeness, and sensation. The likelihood of achieving these goals with BCS, mastectomy with reconstruction, or mastectomy alone is discussed with the patient. Patients with small tumors, relatively large breasts, and/or lesions in the upper outer breast quadrant are considered more suitable candidates for BCS.[19,20]

The relationship between cosmetic outcome, psychological adjustment,[21,22] and quality of life[23] has been well demonstrated. Reports evaluating patient satisfaction with cosmesis after BCS with radiation and after mastectomy with reconstruction have shown differing results. While some studies comparing patient satisfaction favor BCS,[24] others favor mastectomy with reconstruction,[21,25] and others have observed no difference.[26] These findings are likely due to the varied cosmetic results achieved with both procedures, and the complexity of individual perception and expectations. However, regardless of procedure, factors associated with lower patient satisfaction and/or cosmesis are high body mass index (BMI),[22,25,26] delayed wound healing or postoperative complications,[22,26,27] axillary surgery,[22] and radiation boost to the tumor bed.[27] Age did not correlate with satisfaction with cosmesis.[22,26]

Most studies have found that mastectomy alone is associated with the lowest patient satisfaction when compared with BCS or mastectomy with reconstruction.[21,24-26] Guidelines state that all patients undergoing mastectomy should be offered consultation with a plastic surgeon regarding immediate reconstruction.[28] Immediate reconstruction has particular benefits compared with  delayed reconstruction, including a reduction in the number of surgeries, superior cosmesis, and improved restoration of breast appearance and sense of wholeness.[21,25]

Numerous studies have shown that patients who reported taking an active role in deciding between BCS and mastectomy were significantly more satisfied with their decision compared to patients who reported less involvement in the decision-making process. To this end, patient-centred care and education to ensure understanding of expected outcomes have been identified as important factors.[29,30]

Options to improve cosmesis
Breast defects resulting from cancer treatment can be difficult to predict. The tissue fibrosis that occurs with surgery and radiation can evolve over 12 to 18 months following completion of BCS. This process may result in retraction of the lumpectomy site, visible breast volume loss, and/or nipple displacement. Unfortunately, the options for posttreatment surgical correction are limited. Immediate oncoplastic approaches may help to mitigate some of these undesirable effects.[19] Simple approximation of the parenchymal flap at the time of lumpectomy represents an effective method of distributing the volume loss and providing tissue coverage with resultant reduced retraction and change in breast contour. Complex oncoplastic procedures may be undertaken with the participation of a plastic surgeon. These coordinated procedures include a lumpectomy combined with a planned reduction mammoplasty, recentralization of the nipple-areolar complex, and volume replacement.[19] For patients who are candidates for neoadjuvant chemotherapy, preoperative systemic treatment may reduce the primary tumor size prior to BCS and improve cosmesis.[31]

Posttreatment pain
Chronic pain following breast cancer treatment has been reported to affect between 25% and 60% of patients and has been variably defined.[32] As the surgical management of breast cancer has changed over time, particularly regarding the axilla, such historic reports of pain incidence must be interpreted with caution. In a large national cohort study, chronic posttreatment pain was observed in 47% of patients, with a mean time of 26.0 months from surgery to data collection.[33] On a scale of 0 to 10, with 0 representing no pain and 10 representing worst imaginable pain, 48% had light pain (1 to 3), 29% had moderate pain (4 to 6), and 13% had severe pain (7 to 10). In a continuation of this cohort study at a mean time of 72.5 months from surgery, 36% of patients who initially reported pain had persistent pain at follow-up.[34]

The development of posttreatment pain is multifactorial and may result from neuropathic stimuli of surgically damaged nerves, muscular changes at the surgical site, and referred pain from related connective tissues.[35] Factors that can intensify pain and disability and have a negative impact on quality of life include intrinsic nervous system changes (central sensitization), inflammatory processes, and psychosocial factors affecting recovery or timely access to services.[36]

Patient risk factors for the development of posttreatment pain include pre-existing pain, psychosocial determinants, biology, and genetics.[32,33,36] Assessment can aid in identifying patients at risk and allow for implementation of risk-reducing and early intervention strategies.

Pre-existing pain in the breast as well as other anatomic areas not related to the surgery can potentially cause sensitization in the nervous system and changes that are further altered postoperatively. Existing pain may be evaluated using a standard numeric rating scale or a screening instrument for neuropathic pain such as the DN4 questionnaire.[37] Neck and arm range of motion should be assessed and the torso and upper extremity musculature should be palpated to identify dysfunctional movement patterns or tender trigger points that might be aggravated by surgery and need to be addressed preoperatively.

Preoperative psychological risk factors, including depression, anxiety, fear of pain, and catastrophizing, have been observed to affect pain perception and behavior.[36] These factors may be identified with existing screening questionnaires for depression (e.g., Patient Health Questionniare-938), anxiety (e.g., Generalized Anxiety Disorder-739), and functional decline (e.g., Brief Pain Inventory[40]).

Young age is a commonly reported factor for posttreatment pain,[32,33] which may be related to the physiological effects of age or differences in subjective pain expressions. High body mass index has also been observed to increase pain and sensory disturbances,[32,33] possibly due to the increased tissue trauma inherent in surgeries dealing with large breast and axillary volumes and obesity-related sequelae of reduced mobility and nutritional imbalance.[32,33]

Furthermore, genetic variation in individual responses to noxious stimuli and pharmacogenetic variations may influence the development of posttreatment pain and alter response to pain medications.[41]

ALND has been associated with an increased risk of chronic pain when compared with SLNB.[32-34] The underlying mechanism for this is not well understood but may arise from the surgical impact on the intercostobrachial nerves. Interestingly, studies have not identified a significant difference between BCS and mastectomy on the risk of posttreatment pain,[32,34] although one study found proportionately more patients in the mastectomy group with moderate to severe pain.[33] The finding of little difference between BCS and mastectomy may be explained by the common use of radiotherapy in patients undergoing lumpectomy, as the association between radiation treatment and chronic pain is well established.[32-34]

Preoperative interventions
Interventions to prevent the development of chronic posttreatment pain can begin prior to surgery with a multimodal approach that optimizes preoperative health and conditioning.[42] Studies have shown that active coping strategies such as self-management (exercise, distracting activities, and positive self-statements) and obtaining emotional support from others are associated with reduced psychological distress, feelings of helplessness, catastrophizing, and fear, which have all been associated with increased postoperative pain and disability.[36] A practical and simple technique that can be utilized to enhance coping is the box breath: an inspiration of 4 to 8 seconds followed by prolonged breath hold for 3 to 5 seconds, expiration over 4 to 8 seconds, and a rest period of 3 to 5 seconds.[43] Analgesic benefits result from activating the baroreceptor reflex and producing a generalized inhibitory effect on the central nervous system, which includes a reduction in nociception.[43]

Treatment of pre-existing pain utilizing nonpharmacological methods helps reduce opioid use and medication side effects and can improve musculoskeletal function and self-management skills that will be useful in the posttreatment phase.[42]

Intraoperative considerations
Intraoperative local and regional nerve blocks may be effective methods to prevent chronic posttreatment pain. Initial reports on the use of paravertebral nerve blocks have shown decreased chronic pain incidence and pain intensity following breast surgery.[44] Systemic lidocaine and magnesium sulfate have been found to reduce intraoperative and postoperative opioid needs and pain intensity. Intraoperative systemic lidocaine also improved postoperative functional recovery in one trial.[45]

Postoperative interventions
Effective strategies to manage chronic pain that were begun preoperatively can be continued postoperatively to prevent the progression of acute pain to chronic pain. Treatment includes rationalization of analgesics, functional restoration, graded physical reconditioning, and strategies to reduce the impact of pain on daily activities.[42] Early recognition and intervention are key to preventing or reducing the disabilities caused by undertreated pain. Current management approaches are extrapolated from the literature on neuropathic pain and postoperative pain syndromes. Specific pain management options can be applied in the acute and subacute postoperative phase (initial 3 months).[42]

The first few weeks after surgery are critical to modifying pain and its related long-term disabilities. Initially, soft tissue and fascia lose their plasticity and pliability. To counter this effect, patients are encouraged to carry out range of motion exercises immediately following surgery. Optimizing analgesia while avoiding or minimizing use of opioids is preferred and achievable with a multimodal approach. Acetaminophen and anti-inflammatory medications should be used regularly. Daily magnesium malate or bisglycinate supplementation (250 mg to 500 mg) in divided doses has multiple benefits, including pain relief through muscle relaxation, deactivation of receptors associated with hyperalgesia and neuropathic pain, and sleep improvement.[46,47]

Beyond the first 4 weeks, a graded functional restoration approach is recommended. Any patient who deviates from the expected pain recovery trajectory should be identified. Symptoms that raise concern include burning skin, intolerance to light touch, phantom breast sensation, spread of pain beyond the surgical site, shortness of breath, and chest tightness. Initial medication choices include tricyclic antidepressants or anticonvulsants (e.g., pregabalin).[46] Adjunctive therapies such as capsaicin cream, oral mexilitine (a membrane stabilizer), intravenous ketamine, intravenous lidocaine, intravenous steroids, cannabinoids, and dextromethorphan have also been utilized.[48]

Early intervention has been observed to reduce the psychological and physical disabilities associated with undertreated pain. For patients at risk of chronic pain or those with pain beyond 3 months after surgery, early referral to a pain clinic specializing in a multimodal management of neuropathic and myofascial pain should be considered.

The object of surveillance is to identify new primary breast cancers and curable recurrences in the treated breast and axilla. Recommended posttreatment surveillance includes:
•    Breast and nodal examination every 6 months for 5 years, then yearly thereafter.
•    Annual diagnostic bilateral mammo-gram.

Routine CT imaging and blood tests for detection of incurable metastatic disease have not been shown to improve patient outcomes and are not recommended. Posttreatment investigations should be based on patient symptoms.

As our ability to treat and cure breast malignancies continues to improve, more women are navigating life as cancer survivors. For some, the treatment sequelae have significant and long-lasting effects on their physical, emotional, and psychological health. Understanding the long-term risks and impact of treatment can allow physicians to identify survivorship care issues such as arm lymphedema, cosmesis, and posttreatment pain, to base posttreatment cancer surveillance on patient symptoms, and to provide optimal support to patients as they recover from treatment.

Competing interests
Dr Lau is co-founder of the CHANGEpain Clinic, which charges fees for services not covered by MSP and accepts referrals for patients requiring pain management. Drs Chiu and Nichol have no competing interests to declare.

This article has been peer reviewed.

References Top

1.    DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: A systematic review and meta-analysis. Lancet Oncol 2013;14:500-515.
2.    McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: Objective measurements. J Clin Oncol 2008;26:5213-5219.
3.    Whelan TJ, Olivotto IA, Parulekar WR, et al.; MA Study Investigators. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015;373:307-316.
4.    Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001;92:1368-1377.
5.    BC Cancer. Lymphedema. Accessed 23 March 2017.
6.    Asdourian MS, Skolny MN, Brunelle C, et al. Precautions for breast cancer-related lymphoedema: Risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis. Lancet Oncol 2016;17:e392-405.
7.    Mak SS, Yeo W, Lee YM, et al. Risk factors for the initiation and aggravation of lymphoedema after axillary lymph node dissection for breast cancer. Hong Kong Med J 2009;15:8-12.
8.    Showalter SL, Brown JC, Cheville AL, et al. Lifestyle risk factors associated with arm swelling among women with breast cancer. Ann Surg Oncol 2013;20:842-849.
9.    Ferguson CM, Swaroop MN, Horick N, et al. Impact of ipsilateral blood draws, injections, blood pressure measurements, and air travel on the risk of lymphedema for patients treated for breast cancer. J Clin Oncol 2016;34:691-698.
10.    Hershko DD, Stahl S. Safety of elective hand surgery following axillary lymph node dissection for breast cancer. Breast J 2007;13:287-290.
11.    Dawson WJ, Elenz DR, Winchester DP, Feldman JL. Elective hand surgery in the breast cancer patient with prior ipsilateral axillary dissection. Ann Surg Oncol 1995;2:132-137.
12.    Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: A three-year follow-up study. QJM 2005;98:343-348.
13.    McKenzie DC, Kalda AL. Effect of upper extremity exercise on secondary lymphedema in breast cancer patients: A pilot study. J Clin Oncol 2003;21:463-466.
14.    Box RC, Reul-Hirche HM, Bullock-Saxton JE, Furnival CM. Physiotherapy after breast cancer surgery: Results of a randomised controlled study to minimise lymphoedema. Breast Cancer Res Treat 2002;75:51-64.
15.    Torres Lacomba M, Yuste Sanchez MJ, Zapico Goni A, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: Randomised, single blinded, clinical trial. BMJ 2010;340:b5396.
16.    Ezzo J, Manheimer E, McNeely ML, et al. Manual lymphatic drainage for lymphedema following breast cancer treatment. Cochrane Database Syst Rev 2015;(5):CD003475.
17.    Pusic AL, Klassen AF, Scott AM, et al. Development of a new patient-reported outcome measure for breast surgery: The BREAST-Q. Plast Reconstr Surg 2009;124:345-353.
18.    Cohen WA, Mundy LR, Ballard TN, et al. The BREAST-Q in surgical research: A review of the literature 2009-2015. J Plast Reconstr Aesthet Surg 2016;69:149-162.
19.    Silverstein MJ, Mai T, Savalia N, et al. Oncoplastic breast conservation surgery: The new paradigm. J Surg Oncol 2014;110:82-89.
20.    Munshi A, Kakkar S, Bhutani R, et al. Factors influencing cosmetic outcome in breast conservation. Clin Oncol (R Coll Radiol) 2009;21:285-293.
21.    Nicholson RM, Leinster S, Sassoon EM. A comparison of the cosmetic and psychological outcome of breast reconstruction, breast conserving surgery and mastectomy without reconstruction. Breast 2007;16:396-410.
22.    O’Connell RL, DiMicco R, Khabra K, et al. Initial experience of the BREAST-Q breast-conserving therapy module. Breast Cancer Res Treat 2016;160:79-89.
23.    Waljee JF, Hu ES, Ubel PA, et al. Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life. J Clin Oncol 2008;26:3331-3337.
24.    Al-Ghazal SK, Fallowfield L, Blamey RW. Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. Eur J Cancer 2000;36:1938-1943.
25.    Atisha DM, Rushing CN, Samsa GP, et al. A national snapshot of satisfaction with breast cancer procedures. Ann Surg Oncol 2015;22:361-369.
26.    Jagsi R, Li Y, Morrow M, et al. Patient-reported quality of life and satisfaction with cosmetic outcomes after breast conservation and mastectomy with and without reconstruction: Results of a survey of breast cancer survivors. Ann Surg 2015;261:1198-1206.
27.    Vrieling C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol 2000;55:219-232.
28.    American Society of Breast Surgeons. Performance and practice guidelines for mastectomy. Accessed 11 January 2018.
29.    Cohen WA, Ballard TN, Hamill JB, et al. Understanding and optimizing the patient experience in breast reconstruction. Ann Plast Surg 2016;77:237-241.
30.    Ho AL, Klassen AF, Cano S, et al. Optimizing patient-centered care in breast reconstruction: The importance of preoperative information and patient-physician communication. Plast Reconstr Surg 2013;132:212e-220e.
31.    Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: Findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 2014;260:608-614; discussion 614-616.
32.    Andersen KG, Kehlet H. Persistent pain after breast cancer treatment: A critical review of risk factors and strategies for prevention. J Pain 2011;12:725-746.
33.    Gartner R, Jensen MB, Nielsen J, et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 2009;302:1985-1992.
34.    Mejdahl MK, Andersen KG, Gartner R, et al. Persistent pain and sensory disturbances after treatment for breast cancer: Six year nationwide follow-up study. BMJ 2013;346:f1865.
35.    Bordini B, Zanier E. Skin, fascias, and scars: Symptoms and systemic connections. J Multidiscip Healthc 2013;7:11-24.
36.    Sheridan D, Foo I, O’Shea H, et al. Long-term follow-up of pain and emotional characteristics of women after surgery for breast cancer. J Pain Symptom Manage 2012;44:608-614.
37.    Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36.
38.    Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): A diagnostic meta-analysis. J Gen Intern Med 2007;22:1596-1602.
39.    Ruiz MA, Zamorano E, Garcia-Campayo J, et al. Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. J Affect Disord 2011;128:277-286.
40.    Erdemoglu AK, Koc R. Brief Pain Inventory score identifying and discriminating neuropathic and nociceptive pain. Acta Neurol Scand 2013;128:351-358.
41.    Peiro AM, Margarit C, A LL. What is the future of pharmacogenomics in pain management? Pharmacogenomics 2017;18:101-103.
42.    Clarke H, Poon M, Weinrib A, et al. Preventive analgesia and novel strategies for the prevention of chronic post-surgical pain. Drugs 2015;75:339-351.
43.    Reyes del Paso GA, Munoz Ladron de Guevara C, Montoro CI. Breath-holding during exhalation as a simple manipulation to reduce pain perception. Pain Med 2015;16:1835-1841.
44.    Cheng GS, Ilfeld BM. An evidence-based review of the efficacy of perioperative analgesic techniques for breast cancer-related surgery. Pain Med 2017;18:1344-1365.
45.    Kim MH, Lee KY, Park S, et al. Effects of systemic lidocaine versus magnesium administration on postoperative functional recovery and chronic pain in patients undergoing breast cancer surgery: A prospective, randomized, double-blind, comparative clinical trial. PLoS One 2017;12:1-13.
46.    Guerrera MP, Volpe SL, Mao JJ. Therapeutic uses of magnesium. Am Fam Physician 2009;80:157-162.
47.    Vuckovic S, Srebro D, Savic Vujovic K, Postram M. The antinociceptive effects of magnesium sulfate and MK-801 in visceral inflammatory pain model: The role of NO/cGMP/K+ATP pathway. Pharm Biol 2015;53:1621-1627.
48.    Larsson IM, Ahm Sorensen J, Bille C. The post-mastectomy pain syndrome--a systematic review of the treatment modalities. Breast J 2017;23:338-343.

Dr Chiu is a surgical oncologist at Royal Columbian Hospital and Eagle Ridge Hospital, a clinical instructor in the Department of Surgery at UBC, and a member of the Breast Tumour Group of the BC Cancer Surgical Oncology Network. Dr Lau is a pain specialist and anesthesiologist, medical director of the CHANGEpain Clinic, and a clinical associate professor in the Department of Anesthesiology, Pharmacology and Therapeutics at UBC. Dr Nichol is a radiation oncologist at the BC Cancer Vancouver Centre and a clinical professor in the Division of Radiation Oncology and Developmental Radiotherapeutics at UBC.



Arm lymphedema


Posttreatment plan